Syngene International Extends Strategic Partnership with Bristol Myers Squibb Until 2035 Syngene International has announced a contract extension with Bristol Myers Squibb that will last until 2035, strengthening their collaboration in drug development.

Syngene International Extends Strategic Partnership with Bristol Myers Squibb Until 2035 #India #Bengaluru #Bristol_Myers_Squibb #Syngene_International #CRDMO

Syngene International Expands Long-Term Collaboration with Bristol Myers Squibb until 2035 Syngene International has extended its long-term partnership with Bristol Myers Squibb until 2035, enhancing their drug development capabilities and integrated services.

Syngene International Expands Long-Term Collaboration with Bristol Myers Squibb until 2035 #India #Drug_Development #Bangalore #Bristol_Myers_Squibb #Syngene_International

Syngene International and Bristol Myers Squibb Extend Research Partnership to 2035 Syngene International has announced an extension of its research collaboration with Bristol Myers Squibb, enhancing drug development services until 2035.

Syngene International and Bristol Myers Squibb Extend Research Partnership to 2035 #India #Bengaluru #Drug_Development #Bristol_Myers_Squibb #Syngene_International

Syngene International and Bristol Myers Squibb Extend Partnership Until 2035 Syngene International announces the extension of its collaboration with Bristol Myers Squibb through 2035. This partnership enhances drug development services.

Syngene International and Bristol Myers Squibb Extend Partnership Until 2035 #India #Bengaluru #Partnership #Bristol_Myers_Squibb #Syngene_International

Syngene International Expands Bioconjugation Suite for ADC Development Expertise Syngene International is set to enhance its services with a new GMP bioconjugation suite, facilitating end-to-end antibody-drug conjugate development. This expansion will streamline drug development processes for biotech clients.

Syngene International Expands Bioconjugation Suite for ADC Development Expertise #India #Bengaluru #Bioconjugation #ADC_Development #Syngene_International

Syngene International Unveils State-of-the-Art Peptide Laboratory and Automation for Faster Drug Development Syngene International has announced a new peptide laboratory and automation upgrades to streamline drug discovery, fostering faster delivery of therapies.

Syngene International Unveils State-of-the-Art Peptide Laboratory and Automation for Faster Drug Development #India #Bengaluru #Drug_Development #Syngene_International #Peptide_Laboratory

Syngene Expands Operations with First US Manufacturing Facility Acquisition Syngene International has announced the acquisition of its first biologics manufacturing facility in the USA, enhancing global operations and client offerings.

Syngene Expands Operations with First US Manufacturing Facility Acquisition #United_States #Manufacturing #Baltimore #Biologics #Syngene_International